Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
WSD-0628 by Wayshine Biopharma for Glioblastoma Multiforme (GBM): Likelihood of Approval
WSD-0628 is under clinical development by Wayshine Biopharma and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...